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Summary.-The compound 125IUdR can be incorporated in a stable form into the
DNA of cells. The isotope is released if labelled cells or their progeny die. Conse-
quently the rate of 1251 excretion from mice can be used to follow the fate of labelled
cells in vivo. Using these principles we show:
(1) Sufficient label can be incorporated in vitro into both fresh and cryopreserved
human leukaemic myeloblasts, in non-toxic concentrations, to allow their survival in
mice to be estimated by whole-body counting;
(2) The release of isotope from labelled cells is sufficiently slow to offer reasonable
expectation that this technique can be used for assessing the sensitivity of myelo-
blasts to cytotoxic agents in vivo (an application described in the second paper inthis
series, Sonis, Falcao and MacLennon, 1977);
(3) The rate of 1251 excretion from mice injected with myeloblasts from different
donors varies. This probably reflects different rates of spontaneous death of injected
myeloblasts;
(4) Active rejection of myeloblasts starts within 48 h of their injection into mice;
(5) Indirect evidence that phagocytic cells may be active agents in myeloblast
destruction in mice;
(6) Various methods of immunologically depriving mice were assessed to see if
they would result in a useful increase in survival of injected human myeloblasts.
We conclude that there is little advantage and some limitations in using mice thus
deprived;
(7) One of the agents used for immunological deprivation-silica powder-
markedly decreased the rate of 125I loss from mice injected with labelled killed
myeloblasts. This experience emphasizes the importance of including the killed-cell
control in this assay.
THE overall remission rate in acute of sensitivity to drugs, is disappointingly
myeloblastic leukaemia in many centres high.
is over 50%. However, the number of With this in mind, we have set out to
patients who survive the hazards of the establish a technique which could be used
first few weeks of treatment, but still to assess the sensitivity of individual
fail to achieve remission because of lack patients' myeloblasts to various cyto-
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toxic agents in vivo. The model we
describe labels patients' leukaemic myelo-
blasts in vitro with the thymidine analogue
5-125odo-2'-deoxyuridine (125IUdR). The
leukaemic cells are then injected into
mice, and their survival measured by
release of isotope from leukaemic cells.
This release is measured by whole-body
mouse counting, using the techniques
established by Hughes ct al. (1964) and
Commerford (I1965). These workers showed
that IUdR incorporated into DNA is only
released from cells at death. Furthermore,
re-utilisation of released isotope in mice
given iodide in their drinking water to
block thyroid uptake is minimal.
In this paper we report experiments
which establish suitable labelling condi-
tions for both fresh and cryopreserved
human leukaemic myeloblasts. We then
describe observations on the way in which
these labelled cells are handled by normal
and immunologically deprived mice. The
second paper in this series shows how this
technology can be applied to the study of
drug sensitivity in individual patient's
leukaemic cells (Sonis et al., 1977).
MATERIAL AND AIETHODS
Mlyeloblasts.-Myeloblasts were separated
from patients with acute myeloblastic leu-
kaemia (AML). Bone-marrow cells were
collected into heparin (10 ,ul/ml) by sternal
or iliac puncture. Red blood cells and neutro-
phils were then removed by centrifugation
through a Ficoll-Triosil gradient of sp. gr.
1 080. Myeloblasts wrere isolated from venous
blood bv one-g sedimentation. They were
collected either by simple venesection or by
a cell separator (Hemmenetic). The cells
wNere washed once and either used im-
mediately or aliquots containing 5 x 108 to
109 cells in 1 ml of medium with 1000 auto-
logous plasma and 100/, dimethylsulphoxide
were frozen at 1 °C/min and stored over
liquid N2. We are grateful to Professors
Beeson and Weatherall, and Drs Callender,
Emmerson, Sharpe, Pippard and Bunch, for
allowing us to study myeloblasts and serum
from their patients.
Before use, the cells were rapidly thawed
and diluted over 10 min to 20 ml in RPMJI
1640 plus 100) foetal bovine serum (Gibco-
Biocult) and washed twNice. Samples used in
this study comprised over 9000 myeloblasts.
Cultures.-The medium consisted of RPMI
1640, with 20 u/ml of penicillin, 100 ,ug/ml of
streptomycin and fresh glutamine. Different
serum supplements were tested. 12I5UdR
at a specific activity of 25-35 Ci/mmol
(Amersham) wi,as utilised in all the experi-
ments. The optimum concentration of the
isotope wNas investigated and is reported in the
results.
Incubations of myeloblasts and JUdR were
carried out in glass medical flat bottles at
37°C in an atmosphere of 95%o air: 500 Co2.
Varying lengths of time, different volumes of
medium and different cell densities were
tested. At the end of the incubation period,
the cells e-ere flushed from the surface by
injection of medium. They wlere centrifuged
at 200 g for 20 min and resuspended in 20 ml
of fresh RPMI 1640 and cen.trifuged through
2 ml of foetal bovine serum (FBS) which had
been layered under the cell su.spension. This
procedure removes free isotope, which re-
mains above the FBS. The cells were then
suspended in RPMI and the radioactivity
measured in a y counter taking into account
sample volume and well geometry.
Animals and l25JUdR estimation.-A
breeding nucleus of CBA/H T6T6 strain
originallyfrom the M.R.C. Laboratory Animal
Centre was maintained by brother-sister
mating in the Animal House of the Nuffield
Department of Cliniical Medicine, Radcliffe
Infirmary. Mice of either sex were used at
2-4 months of age.
In each experiment, groups of 4-5 animals
of the same sex and age wN-ere utilised.
Uptake of the iodine by the thyroid was
avoided by giving 0-1% KI in the drinking
water, 2 days before the labelled cells were
injected, and for the duration of the experi-
ment.
Three to five x 107 cells in 1 ml of RPAII
were injected i.p. and the radioactivity of
the whole body was measured in a large Nal
well-counter, immediately after injection
and daily thereafter, using the technique of
Hughes et al. (1964).
Effect of serum on phytohaemagylutinin-
stimulate-I blastogenesis.-Fresh frozen serum
from AML patients was tested for its ability
to modify PHA-stimulated blastogenesis of
normal human lymphocytes. The test was
performed using a modification of the whole-
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blood assay described by Maini et al. (1973).
One tenth of a ml of defibrinated whole
blood, 0-1 ml oftest serum, 0 7 ml of medium
(Eagles basal medium with 1% antibiotics
and 1% non-essential amino acids) and 041
ml of PHA at a 1: 300 dilution (Wellcome
Lab reagent grade) were added to (76 x 12
mm) polystyrene culture tubes. These cul-
tures were incubated for 68 h at 37 °C in an
atmosphere of 95% air and 5% CO2. One
,UCi of 3H-thymidine (Amersham) at 1 Ci/
mmol in a volume of 0-05 ml was added, and
the tubes were then incubated for 4 h at 37 'C.
Cold acetic acid (2%) was then added and the
mixture allowed to stand for 10 min. After
centrifugation the cells were wvashed twice
with 500 TCA at 4°C and then washed once
with cold methanol. The tubes were inverted
and the pellets allowed to dry at room
temperature. The dried pellets were then
suspended in 0 3 ml of 041 N NaOH and
0-2 ml of the resulting suspension was
removed and added to 10 ml of scintillation
fluid. Samples were counted in a beta
scintillation counter and allowance made for
background and quenching. Each serum
sample was tested in triplicate.
Conditions for assessing the effect of AML
sera on IUdR uptake by myeloblasts.-
Eighteen x 107 myeloblasts were cultured
for 20 h in 25ml universal vessels. The
culture medium was RPMI with 1000 of
the serum supplement being assessed. At the
end of the culture the cells wvere prepared for
counting as indicated below.
Harvesting cultures labelled with IUdR for
counting in vitro.-Such cultures were centri-
fuged and the pellet was resuspended in 500
trichloroacetic acid (TCA) at 4°C. The
precipitate was then centrifuged, washed in
TCA at 4°C and recentrifuged. The super-
natant was discarded and the residue counted
in a Wallac well scintillation counter.
Irradiated mice.-Mice confined in a narrow
perspex cage received 800 rad whole-body
irradiation from a 60CO source at 45 rad/min.
Animals were used 3 days after irradiation.
The mortality due to irradiation alone was
300/o in the first week (most deaths occur onl
Days 5 and 6).
Thymectomised, irradiated, bone-marrow
reconstituted (B) mice.-Mice were thymecto-
mised at 8 weeks of age following the tech-
nique of Miller (1960). Two weeks later they
were given 850 rad whole-body irradiation
from a 220 KV Westinghouse X-ray machine,
HVL 0 4 mm Cu, focal distance 100 cm, dose
rate 60 rad/min with no added filtration.
Within 2-3 h, the mice were injected with
5 x 106 syngeneic bone-marrow cells. These
immunologically deprived mice (Davies et al.,
1966) were then left for a period of 30 days
before being used.
Trypan blue and silica treatment of animals.
-Trypan blue (BDH) wvas dialysed against
distilled water and diluted in sterile saline to
a concentration of 20 mg/ml. Each animal
was injected i.p. with 5 mg and 1 mg at 24
and 3 h respectively before the injection of
labelled myeloblasts. One-mg s.c. injections
were then given at Days 1 and 3 after
myeloblast transfer. This technique is based
upon the -work of Hibbs (1975).
All mice given a single injection of 10 mg
of trypan blue died.
Powdered silica.-This was a generous gift
from Dr L. Le Bouffant (CERCHAR, B.P.2,
60550 Verneuil-en-Hallatte, France). 8500 of
the granules were <1 1um diameter, 12°/
were 1-2 ,um diameter and <10/ were
>3 ,tm diameter. The agent was given i.p.
as a single injection of 20 mg 24 h before
labelled myeloblasts.
Preparation ofperitoneal cells.-Under brief
ether anaesthesia the mice were injected i.p.
with two 5-ml aliquots of RPMI plus heparin
(10 ,u/ml). The free fluid in the peritoneal
cavity was then drained into universal bottles
(Sterilin). Nucleated cells were counted in an
improved Neubauer counting chamber and
all "smears" were prepared using a cyto-
centrifuge (Shandon). These preparations
w%Nere fixed in methanol and stained with
Giemsa.
Killed cells.-Labelled cells were killed by
twice rapidly freezing (in liquid N2) and
thawing. The cells were then heated at 56°C
for 30 min.
RESULTS
(A) Identification of suitable labelling
conditions
In this section we describe the experi-
ments which led us to formulate a suitable
set of conditions for labelling both fresh
and cryopreserved myeloblasts. The cri-
teria for successful labelling were: firstly,
achieving sufficient counts incorporated
into myeloblasts to enable external detec-
tion by whole-body counting when the
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cells were injected into mice; secondly,
labelling in such a way as to cause
minimum damage to the myeloblasts.
Many of the variables assessed in this
section had to be tested in parallel in large
experiments, but they are dealt with here
one by one for clarity.
(i) Concentration ofIUdR. Myeloblasts
from a number of patients were set up in
20-h cultures with 10% FBS supple-
menting the standard medium. The cells
were at a concentration of 106 cells/ml
and the medium was 1 cm deep in the
culture bottles. Under the conditions
using Amersham 125IUdR at sp. act. 25-35
Ci/mmol it was found that the radio-
chemical had to be used at 0 012)uCi/ml
or less to avoid detectable toxicity to the
myeloblasts. The method for detection of
toxicity was to assess the rate of 125j
excretion from mice injected with myelo-
blasts labelled with IUdR. Fig. I shows a
representative experiment, testing differ-
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ent concentrations oflabel. On the basis of
these experiments, 0 006ytCi/ml was
chosen as a standard labelling concen-
tration. There is no advantage in reducing
the specific activity of label, as fewer
couints are incorporated into myeloblasts
before the threshold of toxicity is reached.
(ii) Ditration of labelling. This is an
important variable. Using 0 006 pCi/ml
at the cell concentrations described above,
it was found that, although as much label
was taken up by the cells within 1 5 h
as by 20 h, only a small proportion of the
label taken up by 1 5 h was precipitable
by 50o TCA at 4°C. On the other hand,
most ofthe label after 20 h was in DNA, as
estimated by TCA precipitation (Fig. 2).
Mice injected with myeloblasts labelled
for 3-5 h were found to lose 65% of their
IUdR (geometric mean of 5 animals) by
the end of the first day after injection,
while mice injected with myeloblasts
labelled for 20 hoturs, only lost 18% of
label during the first day. During the
second and subsequent days, the logarith-
mic loss oflabel was the same in these two
groups.
J) -j
CD
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FIG. 1.-The loss of 125I from mice after i.p.
injection of 5 x 107 JUdR-labelled myelo-
blasts cultured for 20 h in: 0-006 ,uCi/ml
( --- 0); 0-02 ,uCi/ml (O 0) or
0 03 ,uCi/ml (O - - - - - J). (- .... -)
= myeloblasts labelled with 0 006 XCi/ml
and killed before injection. Each point iS
the geometric mean+s.e. of 5 animals in
each group.
1.5 3.5
HR
7 20
FIG. 2. Uptake of 125IUdR by myeloblasts
cultured for varying lengths of time. The
proportion of the total uptake precipitable
by 5 ° TCA at 4 C is showni by shaded
areas. Vertical bars represent + s.e.,
triplicate cultures.
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(iii) Concentration of cells.-Two factors
were considered here: firstly the concen-
tration of cells/ml and secondly the depth
of medium in the bottles. Using 20-h
cultures with 0 006,uCi/ml it was found
that good labelling/cell was achieved at
5 x 105 or 106 cells/ml where the depth
of medium in the bottles was 1 cm.
Greater cell concentrations resulted in less
label being taken up per cell. This reduced
uptake per cell could not be counteracted
by increasing the isotope concentration,
for such increases caused toxicity to
myeloblasts.
(iv) Serum supplement to medium.-
This was an important factor influencing
labelling. Different results were obtained
with different batches of the same type of
serum. While some batches of foetal
bovine serum were satisfactory, the best
results were consistently obtained using
10% heat-inactivated pooled human AB
serum. (We are grateful to Dr H. H.
Gunson for gifts of AB serum.) Hepar-
inised plasma was found to be as good as
serum from the same source. Plasma or
serum from AML patients was generally
satisfactory as long as it was heat-
inactivated. Some fresh AML sera mark-
edly inhibited spontaneous uptake of
IUdR by both autologous and allogeneic
myeloblasts. Consequently we compared
the uptake of IUdR by allogeneic myelo-
blasts, using fresh frozen and heat-
inactivated sera from each of 53 untreated
AML donors (Fig. 3). The results show
that, overall, more IUdR is taken up by
myeloblasts in heat-inactivated as
opposed to fresh sera.
Walker et al. (1973) described an
inhibitory effect ofsera from patients with
AML on the uptake of JUdR by lympho-
cytes transformed with PHA. We, there-
fore, compared the effect of fresh frozen
serum from each of 34 untreated AML
donors on the uptake of IUdR by allo-
geneic myeloblasts, with their effect on
PHA-induced blastogenesis of allogeneic
lymphocytes from normal donors (Fig. 3).
The experimental conditions are described
in the Methods. While very poor [3H]-
50
40
0 30
0
oa 20
10
II~I
i
:
:
II....:
r--
I__ I __ _ , Il_
, *r L-- I IT _ 1
...: I-
100+ 90+ 80+ 70+ 60+ 50+ 40+ 30+ 20+ 10+ <10
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FIG. 3.-The effect on IUdR uptake by
leukaemic myeloblasts from a single donor,
of each of 53 sera from 53 untreated
patients with AML, when the sera are
used as a 10% supplement to culture
medium. .... Fresh frozen serum;
heat activated serum.
The effect on [3H]TdR uptake by
lymphocytes from a single healthy donor
of each of 34 fresh frozen sera from 34
untreated patients with AML, - -- -. The
serum was used as a 10% supplement to
medium which also contained PHA.
[3H]TdR was added to cultures between
68 and 72 h after the cultures were
established.
The results are calculated as the uptake
in an AML serum, as a % of the uptake in
pooled AB serum, and plotted as a histo-
gram. The groups on the horizontal axis are
divided into 10 equal arithmetic groups
where the uptake was less in AML than in
AB serum and an eleventh group where
the uptake was the same or greater than
in AB serum.
TdR uptake by lymphocytes cultured with
PHA occurred in some sera, there was no
correlation between these sera and those
associated with poor IUdR uptake by
myeloblasts. All the sera used were
presentation sera from patients who were
subsequently treated with the Barts III
regimen of chemotherapy for induction of
remission (Powles et al., 1973). We
therefore examined the data for correla-
tion between the degree of these serum
effects and the chance of a serum donor
achieving remission. No correlation was
found in either system, using both the
-*
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Wilcoxon sum of ranks test comparing
remitters and non-remitters, or a x2 test in
which patients were grouped as inhibitors
(i.e. greater than 20% inhibition com-
pared with AB serum pool) and non-
inhibitors, remitters and non-remitters.
(B) The incorporatiGn of IUdR by fresh
versus cryopreserved myeloblasts
Cells were labelled with 0-006 ,uCi/ml
125JUdR for 20 h at the concentration of
cells described above. Viability of the
stored cells was good, whether assessed by
fluorescein diacetate uptake aind conver-
sion or trypan blue exclusion. Although
the rate of uptake of isotope was reduced
between 3 and 7-fold after cryopreserva-
tion (Table), the rate of release of isotope
in mice from cryopreserved cells was
similar to that seen from fresh cells.
(C) Investigation of factors affecting the
survival of rnyeloblasts in mice and attempts
to prolong myeloblast survival
In these experiments myeloblasts were
labelled with 0*006,Ci/mmol JUdR for
TABLE. Incorporation of 125IUdR by 107
Frozen or Fresh Myeloblasts
Counts/min/107 Viability of
cells Frozen Cells
r_ t ,,_ J-Th A
Patient Fresh Frozen %
Trypan
blue
A 903 432 93
B 1440 225
C 630 95
D 1000 234 92
E
F
G
H
I
J
K
L
M
(1500)
5I?V60
(3200)
600
54
500
FDA
90
90
95
20 h. Cells were at a concenitration of
106/ml and the medium was 1 cm deep.
(i) The cellular composition of mouse
peritoneal fluid following the i.p. injection
of labelled myeloblasts. Fifteen mice were
injected with myeloblasts from a single
patient. Five of the mice received IUdR-
labelled cells. This group was counted
each day for 1251 retention. Two of the
mice given unlabelled cells was sacrificed
immediately after injection and further
pairs were killed at 24 h intervals there-
after. The peritoneal fluid from these mice
was washed out with medium. The cells
were counted and a differential count was
performed on a Giemsa-stained film. The
cytological features of the myeloblasts
allowed them to be clearly distinguished
from mouse peritoneal cells. Host cells
were classified as lymphocytes, macro-
phages and neutrophils, on conventional
morphological grounds.
DAYS
Fic. 4. Peritoneal cavity cells after the
injection of 5 x 107 myeloblasts (0 0)
macrophages, (- *) myeloblasts,
(LI O -* * O)lymphocytes and(l (. . U)
polymorphonuclear cells. Each point is
the mean of two animals. (A - * - - - A)=
the release of 1251 from 5 x l07 IUdR-
labelled myeloblasts (geometric mean of 5
mice). Day I is 24 h after injection of
myeloblasts. The mean peritoneal exudate
content of non-injected CBA mice=
neutrophils <01 x 106; lymphocytes, 0-7
x 106; and macrophages, 0-2 x 106.
107
106
x
._
a)
a)
CL
aL)
270 86
288
108
540
90
216
90
93
90
85
90
342 92
(In brackets, bone marrow cells).
Trypan blue uptake was assessed by incubating
in RPM1 with 10% AB serum and 0 25% trypan
blue at 37°C for 5 min.
* Fluorescein diacetate uptake and conversion
carried out according to Bodmer, Tripp and Bodmer
(1967).
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,lute counts of different cell series of experiments designed to answer
,her with the geometric mean this question involved priming mice with
.nt 1251 retention, are shown an i.p. injection of unlabelled myeloblasts
here was a rapid but transient 2 days before giving labelled cells. Fig. 5
neutrophil numbers, so that shows the results of one such experiment,
he most abundant host cell at where 1251 excretion is compared in
h, macrophages had become primed and unprimed mice. It will be
.nt host cell and there was seen that the pre-exposure to myeloblasts
narked diminution of myelo- results in a 24-h advance of the slope of
his stage, frequent myeloblast 1251 excretion. This experiment is highly
interactions were seen, in- reproducible, and myeloblasts from a
gocytosis of myeloblasts. The different donor are equally effective at
between 1251 counts retained inducing accelerated rejection. Although
eal myeloblast content, at this these data do not give any information
one to postulate that either about the specificity of this reaction they
blasts have left the peritoneal do indicate host involvement in the
me are firmly adherent to the destruction of myeloblasts. The next
peritoneum. Experiments with series of experiments was designed to see
ed myeloblasts (Fig. 5) makes whether pretreatment of mice with agents
ie explanation that 1251 is which would suppress various types of
ned for a significant period cytotoxic immunity could delay myelo-
blast death. This experiment blast rejection.
d once, with similar results. (iii) The effect of macrophage blocking on
rice for active host participation myeloblast rejection.-In preliminary ex-
mnyeloblacst death. The first periments, macrophage blocking was
carried out using silica powderinjected i.p.
Thk aonrmt ennvidPrah1v dtclard th.cA rath . -L11 sbJ t5VnUV %VJ1O1%AU1UU1J kA1WJY% V II IUX V S V
of 125J loss from animals injected with
viable myeloblasts. However, it also
markedly reduced the rate of clearance
of 125J from mice given killed cells.
Consequently, for this practical reason,
silica was not considered suitable for use
as an agent to delay myeloblast rejection.
The second macrophage-blocking agent
to be used was trypan blue. This was
found by Beck, Lloyd and Griffiths (1967)
to block lysosome activity, and Hibbs
(1975) used this agent to inhibit tumour-
cell damage by macrophages. Experiments
using this agent, alone and in combination
with whole-body irradiation, are shown in
Figure 6. In otherwise normal mice,
0 1 2 3 4 trypan blue had a marginal slowing
effect on myeloblast rejection. However,
DAYS if mice were given 800 rad 3 days before
ease of 1251 after i.p. injection of injection of myeloblasts, and were also
UdR-labelled myeloblasts into given trypan blue, 1251 excretion was
nal (0 - - -0) and primed markedly retarded. This retardation was
D) with 5 x 107 non-labelled * * *- earlier. Geometric meanos.e. of not associated with loss of ability to
excrete 125I from dead cells. Irradiation
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FiG. 6. Release of 125I after i.p. injection of
3 x 107 live IUd(R-labelled myeloblasts in
normal mice (* .. . ), trypan-blue
treated (A A) (injected i.p. with
5 mg and I mg, 24 and 3 h before the
injection of labelled cells and 1 mg s.c. on
Days 1 and 3), irradiated ( O)
(mice given 800 rad 3 days before injection
of labelled cells) and irradiated + trypan
blue ( 0) mice. MIean + s.e. of 4
animals.
3 x 107 kille(d IUdR-labelled myelo-
blasts were injected into animals prepared
as for each of the four different groups.
The results for all these animals were
essentially the same, and are plotted as a
single line ( n )
alone only marginally reduced the speed
of myeloblast rejection; i.e., both irradia-
tion and trypan blue were required to
produce a significant prolongation of
survival of myeloblasts in mice.
(iv) The effect of T-cell depletion on
myeloblast rejection.-Mice were deprived
of thymus-processed cells as is described
in the Methods. These B mice were tested
in parallel with controls for their capacity
to reject labelled human leukaemic myelo-
blasts.
There was a decrease in the rate of
rejection of about 12-24 h in the B mice
compared with controls. This delay was
0 1 2 3 4 5
DAYS
FiG. 7. Release of 1251 after injection of:
5 x 107 IUdR-labelled live myeloblasts in
normal mice i.p. (O 0) anld S.C.
(0--- 0); 5 X 107 IUdR-labelled
killed myeloblasts in normal mice injected
ip. (- ---- C) an(l s.c. ( .... ).
Meains s.e. for 5 animals.
not increased further by trypan blue
treatment.
(v) Effect of s.c. injection of myeloblasts
on their survival.-The trypan blue and
cytological studies suggested that some
active toxic effect is being expressed
against myeloblasts by macrophages. We,
therefore, set up experiments to see
whether labelled myeloblasts injected s.c.
where there is not a high natural macro-
phage population, lost 1251 more slowly
than those injected i.p. Fig. 7 shows a
representative experiment indicating that
s.c. myeloblasts do indeed survive longer
than the same cells injected i.p.
DISCUSSION
The response of mouse tumour cells to
chemotherapy, irradiation and host im-
munity has been studied bv a number of
workers using the IUdR labelling tech-
nique (Hofer et al., 1969; Hofer, 1970;
Porteous and Munro, 1972). Human leuk-
aemic myeloblasts, however, require rather
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different labelling conditions from those
used for serially transplanted tumours,
which have a uniformly high labelling
index. Short pulses with relatively high
concentration of JUdR are both toxic and
also give poor labelling of myeloblasts.
By the use of low concentrations of this
radiochemical over a prolonged incubation
period, we have shown that it is possible
to label these cells from most patients
with sufficient counts to permit cell-
survival studies to be carried out in mice.
The toxicity and spontaneous release of
125IUdR used in this way compares very
favourably with most pre-labelling tech-
niques used for cytotoxicity testing in
vitro. Consequently, we have progressed
to evaluation of the clinical usefulness of
this technique in assessing drug sensitivity
in AML with some optimism. The second
paper in this series (Sonis et al., 1977)
reports that, in a limited study, the assay
may be able to predict sensitivity to
cytosine arabinoside.
The low labelling index of myeloblasts
(Crowther et al., 1975) does mean that only
a relatively small sample of leukaemic
cells is being labelled. It can beargued that
this actively dividing fraction may not be
representative of all the neoplastic cells.
The only answer to this is practical
evaluation, and the point is considered
further in the next paper. In any case, the
labelling procedure used here is likely to
be at least as representative of the total
neoplasm as cells obtained following
prolonged culture in vitro or serial trans-
plantation in immunologically deprived
animals.
The main advantages of using an in
vivo test system, even if it does cross a
species barrier, is that many cytotoxic
agents, for example cyclophosphamide
and azathioprine, are broken down to
active daughter compounds in vivo.
Obviously, the model we propose cannot
predict an individual's capacity to break
down a drug outside neoplastic cells.
There can be little doubt that much of
the 125J excretion observed in our studies
is due to spontaneous death of myelo-
blasts. However, there does appear to be
some reaction by the mouse to the myelo-
blasts which accelerates loss of 1251
following the injection of viable cells.
This is shown by the consistent finding
that the main slope of 1251 excretion
occurred earlier if unlabelled myeloblasts
were injected 2 days before the labelled
myeloblasts. This cannot just be an effect
on release and excretion of iodide from
dead cells, as the priming had no effect on
the rate of excretion of 125J from mice
injected with dead labelled cells. The
mechanism involved here is unclear,
although a number of the experiments
provide an indirect hint that macrophages
may be involved. The important conclu-
sion to be drawn from the immunological
deprivation experiments is that the tech-
niques of deprivation used do not delay
1251 release sufficiently to be of practical
advantage. Indeed, as they are somewhat
drastic, they might alter the recipient's
capacity to handle cytotoxic agents. In
this context, the marked effect of silica
on the excretion of iodide following
injection ofdead labelled cells is a warning
that the killed-cell control must be
included in all drug evaluation studies.
The growth-inhibiting factors which we
describe in this paper have been recognised
previously. Balkwill, Pindar and Crowther
(1974) found a "complement"-dependent
growth-inhibitory factor in a patient with
AML. Karp and Burke (1976) have also
described an inhibitory effect of this type
in leukaemic patients' serum, which acted
on both normal and leukaemic bone
marrow cells.
Walker et al. (1973) described an
inhibitory effect ofsera from patients with
AML on the mitotic response of normal
lymphocytes to PHA. It is disappointing
that no correlation of these factors with
remission achievement was apparent.
In conclusion we feel that the incidence
of failure to achieve remission through
lack of response to drugs is sufficiently
high to justify the development of predic-
tive tests for drug sensitivity in acute
myeloblastic leukaemia. The technique
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described in this study seems to offer a
practical approachto predictingsensitivity
of an individual patient's myeloblasts to
cytotoxic agents.
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